ClinicalTrials.Veeva

Menu
D

Diakonessenhuis | Obstetrics, Gynecology and Fertility Departments

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Digoxin
Natalizumab
BAY3427080
Capecitabine
Imiquimod
Azithromycin
Milvexian
Amiodarone
Doxorubicin Hydrochloride
5-FU
0

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 66 total trials

A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS)

The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major advers...

Enrolling
Acute Coronary Syndrome
Drug: Milvexian
Other: Placebo

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of t...

Enrolling
Diffuse Large B-Cell Lymphoma
Drug: Epcoritamab
Drug: Cyclophosphamide

The main objective is to determine whether a low-dose regimen of apixaban (2.5 mg bid) is non inferior to a full-dose regimen of apixaban (5 mg bid)...

Active, not recruiting
Cancer-associated Thrombosis
Drug: Apixaban 5 MG

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults wi...

Active, not recruiting
Coronary Heart Disease (CHD)
Drug: Evolocumab
Drug: Placebo

The primary objective of this study is to confirm the safety and efficacy of the RenzanTM Peripheral Stent System when used for treatment of superfic...

Active, not recruiting
Superficial Femoral Artery Disease
Popliteal Artery Disease
Device: Stent implantation

Trial sponsors

U
Maastricht University Medical Centre (MUMC) logo
D
A
R
L
Netherlands Cancer Institute (NKI) logo
S
A
Amgen logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems